Biopharmaceutical company Symic Bio revealed on Thursday the completion of financings led by Cell Innovation Partners (CIP), a healthcare venture fund started by ReproCELL and Shinsei Bank Group in Japan.
Existing investors also participated in the financing.
The total raised amounts to USD11m.
The funds will be used to advance Symic Bio's disease-modifying osteoarthritis drug, SB-061, into a global Phase 2b trial to be started in the latter half of 2019 as well a global Phase 3 trial evaluating the potential for SB-030 to prevent vein graft failure in peripheral artery disease in 2020.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval